← Back to Clinical Trials
Recruiting NCT07367568

NCT07367568 Costotransverse Foramen Block With Erector Spinae Plane Block in Modified Radical Mastectomy

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07367568
Status Recruiting
Phase
Sponsor National Cancer Institute, Egypt
Condition Costotransverse Foramen Block
Study Type INTERVENTIONAL
Enrollment 110 participants
Start Date 2026-01-24
Primary Completion 2026-06-01

Eligibility & Interventions

Sex Female only
Min Age 18 Years
Max Age 65 Years
Study Type INTERVENTIONAL
Interventions
Costotransverse foramen blockErector spinae plane block

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 110 participants in total. It began in 2026-01-24 with a primary completion date of 2026-06-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study aims to compare the costotransverse foramen block with erector spinae plane block in modified radical mastectomy.

Eligibility Criteria

Inclusion Criteria: * Adult females \> 18 years and ≤ 65 years old. * American Society of Anesthesiologists (ASA) physical status П-III. * Body mass index (BMI) 18-35 kg/m2. * Scheduled for modified radical mastectomy. Exclusion Criteria: * Known allergy or hypersensitivity to local anesthetic agents. * Active infection at the injection site (e.g., cellulitis, abscess). * Coagulopathy or ongoing anticoagulant/antiplatelet therapy \[International Normalized Ratio (INR) \> 1.5 or platelet count \< 100,000/µL\]. * Severe respiratory, cardiac, hepatic, or renal disease. * Morbid obesity. * Severe cognitive impairment or uncooperative behavior that could interfere with block placement.

Contact & Investigator

Central Contact

Mai M Elrawas, MD

✉ mai.elrawas@nci.cu.edu.eg

📞 00201222177242

Frequently Asked Questions

Who can join the NCT07367568 clinical trial?

This trial is open to female participants only, aged 18 Years or older, up to 65 Years, studying Costotransverse Foramen Block. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07367568 currently recruiting?

Yes, NCT07367568 is actively recruiting participants. Contact the research team at mai.elrawas@nci.cu.edu.eg for enrollment information.

Where is the NCT07367568 trial being conducted?

This trial is being conducted at Cairo, Egypt.

Who is sponsoring the NCT07367568 clinical trial?

NCT07367568 is sponsored by National Cancer Institute, Egypt. The trial plans to enroll 110 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology